Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.
Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory demyelinating disorder of the central nervous system that leads to permanent neurological deficits. Current MS treatment regimens are insufficient to treat the irreversible neurological disabilities. Tremendous progress in the experimental and clinical applications of cell-based therapies has recognized stem cells as potential candidates for regenerative therapy for many neurodegenerative disorders including MS. Mesenchymal stem cells (MSC) and induced pluripotent stem cell (iPSCs) derived precursor cells can modulate the autoimmune response in the central nervous system (CNS) and promote endogenous remyelination and repair process in animal models. This review highlights studies involving the immunomodulatory and regenerative effects of mesenchymal stem cells and iPSCs derived cells in animal models, and their translation into immunomodulatory and neuroregenerative treatment strategies for MS.
Medical College, Hubei University of Arts and Science, Xiangyang 441053, China. ju_126@126.com.|Department of Biological Treatment, Handan Central Hospital, Handan 056001, China. ju_126@126.com.|Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA. ju_126@126.com.
Juan
J
Xiao
Department of Biological Treatment, Handan Central Hospital, Handan 056001, China. zmhbuas@outlook.com.
Rongbing
R
Yang
Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA. sangita.biswas@ucdmc.ucdavis.edu.
Sangita
S
Biswas
Medical College, Hubei University of Arts and Science, Xiangyang 441053, China. qinxin@fmmu.edu.cn.
Xin
X
Qin
Medical College, Hubei University of Arts and Science, Xiangyang 441053, China. minzhang@ucdavis.edu.
Min
M
Zhang
Medical College, Hubei University of Arts and Science, Xiangyang 441053, China. wbdeng@ucdavis.edu.|Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA. wbdeng@ucdavis.edu.
Wenbin
W
Deng
D000818:Animals; D002490:Central Nervous System / Q000503:physiopathology; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000473:pathology / Q000628:therapy; D005818:Genetic Engineering; D006801:Humans; D056747:Immunomodulation; D007166:Immunosuppressive Agents / Q000737:chemistry; D057026:Induced Pluripotent Stem Cells / Q000166:cytology* / Q000276:immunology; D007249:Inflammation / Q000473:pathology; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology; D051379:Mice; D009103:Multiple Sclerosis / Q000473:pathology / Q000628:therapy*; D009186:Myelin Sheath / Q000737:chemistry; D019636:Neurodegenerative Diseases / Q000276:immunology*; D009474:Neurons / Q000166:cytology; D009836:Oligodendroglia / Q000166:cytology; D012038:Regeneration; D013234:Stem Cells / Q000166:cytology
D007166:Immunosuppressive Agents